Biotech Values

[oc631]

Ritonavir boosting is not the solution—it’s the problem.

Ritonavir boosting isn't the only problem with RG7227. I would prefer to see Roche use lower doses of RG7227 without boosting in INFORM-3, with the option of licensing a guanine nuke if needed, to boost the potency and/or resistance profile of the existing combination. It's easy to overlook the potential of this DAA, which may be the first to market, by focusing too much on the weaker half.